Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd

SHSE:688336 Stock Report

Market Cap: CN¥10.3b

Sunshine Guojian Pharmaceutical (Shanghai) Future Growth

Future criteria checks 0/6

Sunshine Guojian Pharmaceutical (Shanghai)'s earnings are forecast to decline at 0.8% per annum while its annual revenue is expected to grow at 11% per year. EPS is expected to decline by 1.4% per annum. Return on equity is forecast to be 5.4% in 3 years.

Key information

-0.8%

Earnings growth rate

-1.4%

EPS growth rate

Biotechs earnings growth39.7%
Revenue growth rate11.0%
Future return on equity5.4%
Analyst coverage

Low

Last updated07 Sep 2024

Recent future growth updates

Recent updates

What Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd's (SHSE:688336) P/E Is Not Telling You

Jul 25
What Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd's (SHSE:688336) P/E Is Not Telling You

Is Sunshine Guojian Pharmaceutical (Shanghai) (SHSE:688336) A Risky Investment?

Jun 20
Is Sunshine Guojian Pharmaceutical (Shanghai) (SHSE:688336) A Risky Investment?

If EPS Growth Is Important To You, Sunshine Guojian Pharmaceutical (Shanghai) (SHSE:688336) Presents An Opportunity

May 24
If EPS Growth Is Important To You, Sunshine Guojian Pharmaceutical (Shanghai) (SHSE:688336) Presents An Opportunity

We Think That There Are Issues Underlying Sunshine Guojian Pharmaceutical (Shanghai)'s (SHSE:688336) Earnings

Mar 31
We Think That There Are Issues Underlying Sunshine Guojian Pharmaceutical (Shanghai)'s (SHSE:688336) Earnings

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHSE:688336) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Mar 04
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHSE:688336) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Earnings and Revenue Growth Forecasts

SHSE:688336 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20261,525331N/A2713
12/31/20251,334281N/A2883
12/31/20241,263320N/A6423
6/30/20241,133329229395N/A
3/31/20241,074352296461N/A
12/31/20231,014295181416N/A
9/30/20231,04424352382N/A
6/30/2023963151-59284N/A
3/31/202387282-98208N/A
12/31/20228254912233N/A
9/30/202282814-13245N/A
6/30/2022791-12-16039N/A
3/31/202293450-330-80N/A
12/31/202192918-508-244N/A
9/30/2021697-155-450-205N/A
6/30/2021783-137-461-205N/A
3/31/2021757-148-352-124N/A
12/31/2020655-217-267-40N/A
9/30/20201,009117-2227N/A
6/30/20201,011154220398N/A
3/31/20201,155194N/AN/AN/A
12/31/20191,177229457588N/A
12/31/20181,142370271361N/A
12/31/20171,103389N/A235N/A
12/31/2015877211N/A336N/A
12/31/2014776212N/A264N/A
12/31/2013728295N/A276N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 688336's earnings are forecast to decline over the next 3 years (-0.8% per year).

Earnings vs Market: 688336's earnings are forecast to decline over the next 3 years (-0.8% per year).

High Growth Earnings: 688336's earnings are forecast to decline over the next 3 years.

Revenue vs Market: 688336's revenue (11% per year) is forecast to grow slower than the CN market (13.1% per year).

High Growth Revenue: 688336's revenue (11% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 688336's Return on Equity is forecast to be low in 3 years time (5.4%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y